David Stephens
Nurse Practitioner · Tyler, TXNPI 1851805055
Payments from drug & device makers
Across 456 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Novo Nordisk$1K
- Boehringer Ingelheim$744
- Lilly USA, LLC$664
- Corium, LLC$446
- plus $3K from 33 others
What the payments were for
- Food & beverage$9,356100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,356 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $137,836 |
| JardianceEmpagliflozin | 103 | $116,229 |
| RybelsusSemaglutide | 35 | $75,368 |
| EliquisApixaban | 76 | $75,021 |
| MounjaroTirzepatide | 68 | $71,003 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $70,207 |
| FarxigaDapagliflozin Propanediol | 50 | $52,782 |
| TrulicityDulaglutide | 20 | $18,225 |
| LivaloPitavastatin Calcium | 11 | $6,721 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $6,666 |
| Gabapentin | 219 | $4,158 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 124 | $2,888 |
| Telmisartan | 94 | $2,577 |
| PremarinEstrogens, Conjugated | 13 | $2,558 |
| Levothyroxine Sodium | 254 | $2,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,037 | $213,204117 claims |
| Boehringer IngelheimJardiance | $744 | $116,229103 claims |
| Lilly USA, LLCMounjaro, Trulicity | $664 | $89,22888 claims |
| PfizerEliquis, Premarin | $199 | $77,57889 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,716 | $76,872110 claims |
| AstraZenecaFarxiga | $1,413 | $52,78250 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $85 | $6,72111 claims |
| AbbVieSynthroid | $177 | $1,27029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Tyler
- Roger ChapmanTyler$211K
- David McCaskillTyler$27K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Monica WhiteLongview$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.